Weight Loss · GLP-1 Comparison · Brandon, FL
Semaglutide vs Tirzepatide
Two of the most effective weight loss medications available, side by side. Here is how they differ in results, mechanism, dosing, side effects, and cost, and how to choose the right one with your provider.
Semaglutide vs tirzepatide: what is the difference?
Both are weekly injectable GLP-1 medications that reduce appetite and support significant weight loss. The core difference is how many receptors they target.
Semaglutide activates a single receptor, GLP-1. Tirzepatide is a dual agonist that activates both GIP and GLP-1 receptors, which is thought to explain its larger average weight loss in clinical trials. That does not automatically make it the right choice for everyone: goals, medical history, tolerability, and cost all factor in. Many patients reach their goals comfortably on semaglutide. The right answer is the one you and your provider choose together.
| Semaglutide | Tirzepatide | |
|---|---|---|
| Mechanism | Single GLP-1 agonist | Dual GIP / GLP-1 agonist |
| Avg weight loss (trials) | About 15% | Up to about 21% |
| Administration | Weekly injection | Weekly injection |
| Brand names | Ozempic®, Wegovy® | Mounjaro®, Zepbound® |
| Side effects | Mostly GI, ease with titration | Mostly GI, ease with titration |
| Often best for | A proven, often more economical start | Maximum results or a plateau on semaglutide |
Which one is right for you?
Semaglutide vs Tirzepatide, Frequently Asked Questions
Curious about cost? Your cost depends on the option that fits your case, which we map out at your consultation. The treatment you’re interested in might be on sale this month, so see our pricing page for current rates and check this month’s specials.
This information is provided for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Individual results vary. Always consult a qualified healthcare provider about your specific situation.
Clinical References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. Mean body weight change of −14.9% at week 68 (STEP 1).
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. Mean body weight reduction of 15.0%, 19.5% and 20.9% at 72 weeks for the 5 mg, 10 mg and 15 mg doses (SURMOUNT-1).
Trial results reflect study populations under clinical supervision alongside lifestyle intervention. Individual results vary.
Still Deciding?
Let a provider help you choose, no obligation
A medical provider will review your goals and health history and recommend whether semaglutide or tirzepatide is the better fit. Schedule your complimentary consultation.
Stay in the loop
Get the latest treatments, provider tips, and news from Florida Aesthetics & Wellness delivered to your inbox.